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Chronic Kidney Disease in Cats and the Risk of Total Hypercalcemia
D.H.N. van den Broek, Y.-M. Chang, J. Elliott, and R.E. Jepson
Background: Chronic kidney disease (CKD) is a common comorbidity in cats with hypercalcemia, but whether CKD is a
risk factor for hypercalcemia is unclear. Hypercalcemia often is diagnosed based on total calcium concentration (tCa), which
tends to underestimate the ionized calcium concentration (iCa) in cats.
Objectives: Assessment of the performance of tCa for the diagnosis of ionized hypercalcemia, and exploration of factors
influencing the relationship between iCa and tCa. Determination of risk factors for incident total hypercalcemia (ie, the devel-
opment of hypercalcemia based on tCa during follow-up).
Animals: Records of a cross-section (n = 477) and observational cohort (n = 367) of client-owned cats with and without
azotemic CKD from first opinion practice.
Methods: Retrospective cross-sectional and retrospective cohort study. The diagnostic accuracy of tCa as an index test for ion-
ized hypercalcemia was evaluated, and risk factors for underestimation were explored by binary logistic and linear regression in a
cross-section of cats with and without azotemic CKD. Chronic kidney disease and clinicopathological variables were assessed as pre-
dictors of incident total hypercalcemia by both time-invariant and time-dependent Cox regression in a cohort of cats.
Results: Specificity of tCa for identification of ionized hypercalcemia was high (100%), but sensitivity was low. Underesti-
mation was associated with lower venous bicarbonate concentrations. Cats with CKD had increased risk for incident total
hypercalcemia (hazard ratio, 4.29; 95% confidence interval, 1.96–9.37; P < .001). Higher tCa predicted incident total hyper-
calcemia in both azotemic and nonazotemic cats (P < .001).
Conclusions and Clinical Importance: Chronic kidney disease is a risk factor for incident total hypercalcemia, and most
cats with increased tCa had concurrent ionized hypercalcemia. Higher baseline tCa predicts incident total hypercalcemia.
Prospective studies assessing changes in iCa are warranted.
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Hypercalcemia in cats is associated with chronic kid-ney disease (CKD), neoplasia, and rarely primary
hyperparathyroidism,1–3 although hypercalcemia of
idiopathic origin is considered the most common
etiology.4 It is unclear whether renal dysfunction is truly
a risk factor for the development of hypercalcemia,
because CKD is a common comorbidity in older cats,5,6
and hypercalcemia could decrease glomerular filtration
rate4 by decreasing medullary tonicity7 and renal blood
flow.8 Several mechanisms by which CKD may con-
tribute to hypercalcemia have been proposed, including
decreased glomerular filtration, increased tubular reab-
sorption, and decreased bone storage of calcium.9 Based
on total calcium concentration (tCa), early studies
report CKD in 25% of hypercalcemic cats,2 whereas
hypercalcemia was found in 11.5–21% of cats with
CKD.1,3,10 The prevalence appears to increase as renal
function declines, from 8% in early stage to 32% in
end-stage disease.1 Approximately half of tCa consists
of hydrated free calcium ions, and the other half con-
sists of protein-bound calcium and a small but variable
portion of ionic complexes, such as calcium
phosphate.9,11 Hypercalcemia in CKD typically is repre-
sented by an increase in tCa, with a normal ionized cal-
cium concentration (iCa).12–14 Ionized hypercalcemia
has been reported in 10–30% of cats with CKD,1,10
even though iCa tends to decrease in end-stage disease.1
The ionized calcium fraction is biologically active and
therefore superior to tCa in assessing calcium status.11
Due to practical implications, however, tCa is often
relied on in practice.11 The sensitivity and specificity of
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tCa to predict ionized hypercalcemia in cats with CKD
are reported to be 30 and 92%, respectively.10 Hypoal-
buminemia, causing a decrease in the protein-bound
fraction, could result in underestimation of ionized
calcium.10,15 However, tCa and albumin concentrations
correlate poorly, and the diagnostic accuracy of tCa
could not be improved by adjustment for serum albu-
min concentration in cats.16,17 In addition to hypoalbu-
minemia, metabolic acidosis appears to increase the risk
for underestimation of iCa in human CKD,15 but this
has not been reported in cats.
The aims of our study were as follows: first, to assess
the performance of plasma tCa in the prediction of ion-
ized hypercalcemia and explore factors influencing the
relationship between iCa and tCa, and second, to deter-
mine whether azotemic CKD is a risk factor for the
development of total hypercalcemia and to explore pre-
dictors of incident total hypercalcemia.
Materials and Methods
Case Selection
Cases were retrospectively selected from the records of geriatric
cat clinics held at 2 London-based first opinion practices (People’s
Dispensary for Sick Animals in Bow and Beaumont Sainsbury
Animal Hospital in Camden), where apparently healthy cats
(≥9 years) had blood samples collected every 6 months for general
health screening, and cats with CKD or systemic hypertension
were blood sampled every 4 months for disease management. Cri-
teria for a diagnosis of azotemic CKD were plasma creatinine con-
centration ≥2 mg/dL in conjunction with a urine specific gravity
(USG) <1.035, or plasma creatinine concentration ≥2 mg/dL on 2
consecutive occasions 2–4 weeks apart. Records of cats with clini-
cal signs of hyperthyroidism, plasma total thyroxine concentration
>40 nmol/L, medical treatment for hyperthyroidism, or diabetes
mellitus, or treatment with corticosteroids were excluded from all
analyses. Cats receiving amlodipine besylate for treatment of sys-
temic hypertension were included.
Collection and storage of blood samples was performed with
owner consent and approval of the Ethics and Welfare Committee
of the Royal Veterinary College. Blood was obtained by jugular
venipuncture, collected in a heparinized tube, and stored on ice for
a maximum of 6 hours until centrifugation and separation. Hepar-
inized plasma was sent to an external laboratorya for routine bio-
chemistry, including tCa. Ionized calcium concentration was
measured in nonheparinized whole blood immediately after
venipuncture using a point-of-care analyzer,b which also reported
venous bicarbonate concentration (HCO3
). Venous HCO3
 is an
accurate substitution for arterial HCO3
 in humans.18,19 Time
between iCa and tCa measurement was 24 hours. Results of intact
fibroblast growth factor 23 (FGF-23), intact parathyroid hormone
(PTH), calcidiol, and calcitriol concentrations were available for
some cats. Fibroblast growth factor 23 and PTH had been mea-
sured in EDTA plasma using validated20,21 ELISAc and immuno-
radiometricd assays, respectively. Calcidiol and calcitriol had been
measured at an external commercial laboratory.e
Evaluation of Diagnostic Accuracy of tCa as a
Marker of Ionized Hypercalcemia
For the cross-sectional analysis assessing the diagnostic perfor-
mance of tCa for the detection of ionized hypercalcemia, patient
records from January 1, 2000 to December 31, 2015 were reviewed
for cats that had both iCa and tCa measured on the same blood
sample. If cats had both tCa and iCa measured on multiple occa-
sions, only the first visit on which this occurred was included.
Hypercalcemia was diagnosed based on a 95% reference interval
for iCa in older cats (4.76–5.48 mg/dL) previously derived using
an identical analyzer.22 Ionized calcium status was compared to
the matched total calcium status for which the laboratory refer-
ence interval (8.20–11.80 mg/dL) was used.
Evaluation of Risk of Incident Total Hypercalcemia in
Cats with and Without Renal Azotemia
For the retrospective cohort, the records between January 1,
2000 and September 1, 2014 were reviewed to identify nona-
zotemic cats and cats with a diagnosis of azotemic CKD. Data
extraction was performed on July 27, 2015. For nonazotemic cats,
the first visit to the geriatric cat clinic was designated as baseline,
whereas for CKD cases the date of diagnosis of azotemic CKD
was used. All records were included from baseline to the visit
when total hypercalcemia was noted (ie, incident total hypercal-
cemia; tCa >11.80 mg/dL). Animals that remained normocalcemic
based on tCa had to have follow-up of at least 330 days to be
included. Cases with a diagnosis of total hypercalcemia before or
at baseline were excluded. Cats were classified according to renal
azotemia and development of total hypercalcemia, resulting in the
following 4 groups: cats with a diagnosis of CKD that remained
normocalcemic during follow-up (CKD-NCa group); cats with a
diagnosis of CKD that developed total hypercalcemia (CKD-HCa
group); nonazotemic cats that remained normocalcemic (H-NCa
group); and nonazotemic cats that developed total hypercalcemia
(H-HCa group).
Statistical Analysis
All statistical analyses were performed using commercial
software.f Statistical significance was set as P < .05. Continuous
clinical data are presented as mean (range) or median [25th and
75th percentiles]. Normality was assessed by visual inspection of
histograms, and skewed variables were log-transformed for nor-
malization. Correlations were assessed by Pearson’s correlation (r).
Evaluation of Diagnostic Accuracy of tCa as a
Marker of Ionized Hypercalcemia
Simple linear regression was used to assess the association
between tCa and iCa. Sensitivity and specificity were calculated
for tCa as an index test of true ionized hypercalcemia. Measures
of accuracy are presented as percentage (95% confidence interval
[CI]). Receiver operating characteristic (ROC) curves were plotted
to assess overall diagnostic accuracy of tCa for detecting ionized
hypercalcemia. Age, sex, weight, creatinine, phosphate, albumin,
cholesterol, sodium, potassium, chloride, HCO3
, pH, and PCV
were assessed as risk factors by binary logistic regression with
underestimation of iCa status as the event of interest. Only ionized
hypercalcemic cats were used in this analysis, classified as either
underestimated (total normocalcemia with ionized hypercalcemia)
or in agreement (both total and ionized hypercalcemia). Only vari-
ables from the univariable analysis with a type I error <10% were
entered into multivariable logistic regression analysis. The final
models were derived by backward elimination. Results are
reported as odds ratio (OR) (95% CI).
In addition to dichotomization of cases as either underestimated
or in agreement based on reference ranges, the amount of underes-
timation was quantified by standardizing tCa and iCa using the
formula: z-score = (measured value  reference range mean)/stan-
dard deviation of the reference range.15,23,24 Cats were classified as
underestimated if the standard score of tCa was lower than the
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standard score of the matching iCa value (z-score tCa  z-score
iCa < 0). Linear regression was used to explore what variables
influence tCa in cats in which tCa underestimates iCa. Variables
with a type I error <10% entered multivariable linear regression.
The final models were derived by backward elimination. Results
are reported as regression coefficient (b) (95% CI).
Evaluation of Risk of Incident Total Hypercalcemia in
Cats with and Without Renal Azotemia
Baseline variables of the 4 groups were compared using 1-way
ANOVA with Bonferroni posthoc comparison or independent
samples t-test and proportions by Fisher’s exact test. To assess
whether azotemic CKD is a risk factor for incident total hypercal-
cemia, Kaplan–Meier curves of the nonazotemic and CKD group
were compared using log-rank test, and a hazard ratio (HR) was
calculated with univariable Cox proportional hazard analysis. Inci-
dent total hypercalcemia was the event of interest, and cats that
remained normocalcemic were censored when lost to follow-up.
Cats with CKD had blood samples collected more frequently (ev-
ery 4 months) because of their condition than did nonazotemic
cats (every 6 months). A subanalysis that only included visits at 6-
month intervals, ignoring other visits, was carried out to evaluate
the above-mentioned potential bias.
Baseline predictors of incident total hypercalcemia for the azo-
temic and nonazotemic groups were explored with time-invariant
Cox regression, and repeatedly measured predictors were assessed
using time-dependent Cox regression. No missing data imputation
was performed. Age, weight, USG, iCa, and plasma creatinine,
phosphate, tCa, FGF-23, chloride, sodium, and potassium concen-
trations were entered as continuous variables, and hair length, sex,
and plasma albumin and PTH concentrations based on terciles, as
categorical variables. Variables with a type I error <10% entered
multivariable analysis. The final time-invariant and time-dependent
models were derived by backward elimination. Results are
reported as HR (95% CI). Receiver operating characteristic curves
were constructed to explore cutoff values of baseline predictors of
incident total hypercalcemia.
Results
Evaluation of Diagnostic Accuracy of tCa as a
Marker of Ionized Hypercalcemia
A total of 590 independent samples were identified
with both tCa and iCa measured, of which 113 were
excluded because of a diagnosis of hyperthyroidism
(n = 85), or undetermined renal function (n = 28),
allowing 477 cats for analysis, of which 168 were nona-
zotemic and 309 had CKD. Domestic shorthair was the
most common breed (n = 368), followed by domestic
longhair (n = 51), and purebreds or crosses of the fol-
lowing breeds: Burmese (n = 15), Persian (n = 15), Sia-
mese (n = 8), Birman (n = 4), 3 each of British blue,
British shorthair, Chinchilla, and Russian blue, 2 Maine
Coons, 1 Abyssinian, and 1 Tiffany. In the CKD group,
222 cats had International Renal Interest Society (IRIS)
(www.iris-kidney.com) stage 2; 66, IRIS stage 3; and 21,
IRIS stage 4 CKD. Clinicopathologic variables are
summarized in Table 1. Based on iCa, 58 cats were
hypercalcemic, 31 hypocalcemic, and 388 normocal-
cemic. In ionized hypercalcemic cats, mean iCa was
5.91 (range, 5.52–7.40) mg/dL and mean tCa 11.20
(range, 9.48–14.84) mg/dL. No concurrent diseases
other than CKD, hypertension, or bacterial urinary
tract infections were diagnosed.
The association between tCa and iCa was moderate
in both groups (r = 0.62 for the nonazotemic group and
r = 0.63 for the azotemic group, Fig 1). Total calcium
concentration was significantly associated with iCa
(P < .001), with 0.28 (95% CI, 0.22–0.33) mg/dL and
0.31 (95% CI, 0.27–0.36) mg/dL increase in iCa per
1 mg/dL increase in tCa in the nonazotemic and azote-
mic groups, respectively (R2, 0.39 for both groups).
Ionized hypercalcemia was correctly identified in 13 of
47 CKD cases and in 1 of 11 nonazotemic cases based
on tCa. Sensitivity of tCa >11.80 mg/dL to detect ion-
ized hypercalcemia was 27.7% (95% CI, 16.9–41.8) in
CKD cats and 9.1% (95% CI, 1.6–37.7) in the nona-
zotemic group. Specificity was 99.6% (95% CI, 97.9–
99.9) in azotemic and 100% (95% CI, 97.6–100) in non-
azotemic cats. The area under the ROC curve
(AUROC) was 0.80 (95% CI, 0.73–0.87) for CKD cats
and 0.97 (95% CI, 0.93–1.00) for nonazotemic cats. The
ROC curve analysis indicated that in the CKD group,
sensitivity and specificity would be 72.3% (95% CI,
57.4–84.4) and 71.0% (95% CI, 65.1–76.4), respectively,
if a lower tCa cutoff of 10.3 mg/dL had been used to
diagnose ionized hypercalcemia. In the nonazotemic
group, 90.9% (95% CI, 58.7–99.8) sensitivity and
94.9% (95% CI, 90.2–97.8) specificity were predicted
for a cutoff of 10.5 mg/dL.
Table 1. Clinicopathologic variables for cats included in
the cross-sectional study grouped according to renal status.
Variable
(Reference Interval)
CKD
(n = 309)
Nonazotemic
(n = 168)
Median [25th,
75th Percentile]
Median [25th,
75th Percentile]
Age (years) 14.4 [11.4, 16.6] 12.3 [11.0, 14.6]
Weight (kg) 3.90 [3.20, 4.54] 4.25 [3.43, 5.04]
% Male 55.5 50.6
Albumin (2.5–4.5 g/dL) 3.2 [3.0, 3.3] 3.2 [3.0, 3.4]
Chloride
(100–124 mEq/L)
119 [116, 122] 120 [118, 122]
Creatinine
(0.23–2.00 mg/dL)
2.48 [2.17, 2.91] 1.53 [1.38, 1.73]
HCO3
 (17–24 mEq/L) 20 [18, 22] 20 [19, 22]
iCa (4.76–5.48 mg/dL) 5.16 [5.00, 5.36] 5.12 [4.96, 5.27]
PCV (30–45%) 34 [30, 38] 37 [33, 40]
Venous pH (7.21–7.44) 7.36 [7.31, 7.39] 7.36 [7.32, 7.39]
Phosphate
(2.79–6.81 mg/dL)
3.93 [3.41, 5.05] 3.60 [3.14, 4.11]
Potassium
(3.5–5.5 mEq/L)
3.7 [3.5, 4.0] 3.7 [3.4, 3.9]
Sodium
(145–157 mEq/L)
151 [150, 153] 151 [150, 152]
tCa (8.2–11.8 mg/dL) 10.2 [9.7, 10.5] 9.7 [9.4, 10.2]
Total protein
(6.0–8.0 g/dL)
7.6 [7.3, 8.0] 7.7 [7.3, 8.1]
USG (≥1.035) 1.018 [1.015, 1.021] 1.043 [1.030, 1.050]
CKD, chronic kidney disease; n, number of cats; HCO3
,
venous bicarbonate; iCa, ionized calcium; tCa, total calcium;
USG, urine specific gravity.
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With binary logistic regression analysis, lower HCO3

was identified as a significant risk factor for underestima-
tion of calcium status if the azotemic and nonazotemic ion-
ized hypercalcemic cats were combined for analysis (OR,
0.74; 95% CI, 0.55–0.93; P = .007), but not when the
CKD group was analyzed separately (n = 47; P = .062).
The standardized tCa was lower than the standard-
ized iCa in 171 cats with CKD and 99 nonazotemic
cats. Linear regression analysis was performed to assess
what variables influenced plasma tCa in these
underestimated cases. Venous HCO3
, and plasma crea-
tinine and albumin concentrations were associated with
plasma tCa at the 10% level in both groups (Table 2).
In the multivariable models adjusted for iCa, HCO3,
creatinine, and albumin concentrations remained signifi-
cant in the CKD group, and albumin and HCO3
 con-
centrations in the nonazotemic group.
Evaluation of Risk of Incident Total Hypercalcemia in
Cats with and Without Renal Azotemia
For the observational cohort, 2,198 cats were identi-
fied, of which 1,818 were excluded from analysis
because of insufficient follow-up (n = 566), suspect or
documented hyperthyroidism during follow-up
(n = 1251), and corticosteroid administration (n = 1).
Thereafter, 13 cats were excluded for total hypercal-
cemia at baseline. In total, 367 cats were included: 176
nonazotemic cats, of which 10 developed total hypercal-
cemia, and 191 cats with a diagnosis of azotemic CKD,
of which 60 developed total hypercalcemia. Most com-
mon breeds were domestic shorthair (n = 270) followed
by domestic longhair (n = 41), and purebreds or cross-
breeds of Burmese (n = 15), Persian (n = 14), Siamese
(n = 6), British shorthair (n = 5), British blue (n = 3), 2
each of Russian blue, Tiffany, Bengal, and Exotic short-
hair, and 1 each of Abyssinian, Maine Coon, American
shorthair, Devon rex, and Ocicat. Of the 191 cats with
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Fig 1. Scatter plots illustrating the relationship between plasma
tCa and whole blood iCa in (A) azotemic (n = 309) and (B) nona-
zotemic (n = 168) cats. Diagonal black lines represent regression
lines. Dashed lines represent the lower and upper limits of the ref-
erence intervals for plasma tCa (8.20–11.80 mg/dL) and whole
blood iCa (4.76–5.48 mg/dL). r, Pearson’s correlation coefficient.
Table 2. Univariable and multivariable linear regres-
sion models to identify predictors of plasma total cal-
cium concentration in azotemic and nonazotemic cats
with underestimated ionized calcium concentration.
Univariable
Results
Multivariable
Results
b (95% CI) P b (95% CI) P
CKD cats (n = 171)
Ionized
calcium
(mg/dL)
1.89 (1.65–2.13) <.001 1.74 (1.50–1.97) <.001
HCO3

(mEq/L)
0.08 (0.03–0.13) .002 0.06 (0.03–0.09) <.001
Creatinine
(mg/dL)
0.30 (0.09–0.51) .005 0.23 (0.09–0.38) .001
Albumin
(g/dL)
0.62 (0.15–1.09) .010 0.48 (0.17–0.78) .002
Nonazotemic cats (n = 99)
Ionized
calcium
(mg/dL)
2.03 (1.71–2.35) <.001 1.92 (1.66–2.19) <.001
Albumin
(g/dL)
0.87 (0.49–1.26) <.001 0.68 (0.47–0.89) <.001
HCO3

(mEq/L)
0.05 (0.00–0.11) .065 0.04 (0.02–0.07) .002
Creatinine
(mg/dL)
0.52 (0.02–1.02) .042
CKD, chronic kidney disease; b, regression coefficient; 95% CI,
95% confidence interval; HCO3
, venous bicarbonate; P, significance.
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CKD, 143 had IRIS stage 2, 46 IRIS stage 3, and 2
IRIS stage 4 CKD. Forty-six of the cats that developed
total hypercalcemia were part of the study population
used for the cross-sectional analysis, with 3 visits being
identical. Baseline values of clinicopathologic variables
can be found in Table 3. Baseline tCa was higher in
both nonazotemic and azotemic cats that developed
total hypercalcemia during follow-up, and iCa was
higher in the CKD-HCa group. Baseline plasma intact
PTH concentration was lower in cats that developed
total hypercalcemia. Plasma creatinine concentration
did not differ between cats that developed total hyper-
calcemia and cats that remained normocalcemic in each
group.
At the hypercalcemic visit, mean tCa was 12.74
(range, 11.92–14.16) mg/dL for nonazotemic cats and
12.72 (range, 11.84–19.08) mg/dL for CKD cats. Data
on iCa were available for 2 nonazotemic cats (6.16 and
6.60 mg/dL) and 18 CKD cats (mean, 6.31; range,
5.48–7.40 mg/dL). All but 1 had concurrent ionized
hypercalcemia. Median phosphate concentration was
3.52 [2.57, 4.09] mg/dL in nonazotemic and 4.23 [3.58,
5.19] mg/dL in azotemic cats. In CKD cats, median
plasma creatinine concentration was 2.44 [2.23, 3.07]
mg/dL, and a >25% increase compared to baseline was
observed in 8 cats. Parathyroid hormone concentration
was <2.6 pg/mL in 7 and 8.0 pg/mL in 1 cat, and
decreased compared to baseline in 5 cats (baseline med-
ian, 21.5 [9.0, 47.8] pg/mL). Five cats were treated PO
with aluminum hydroxide. Concurrent findings with
total hypercalcemia were abdominal masses (n = 2), cal-
cium oxalate crystalluria (n = 2), and ureterolithiasis
(n = 1).
The incidence rate of total hypercalcemia was 0.03
per patient-year for the nonazotemic group and 0.18
per patient-year for the CKD group. Risk of total
hypercalcemia within the first year from baseline was
2.3% for nonazotemic cats and 23.4% for CKD cats.
The Kaplan-Meier curves (Fig 2A) were significantly
different between the 2 groups (P < .001), and cats with
azotemic CKD were at significantly higher risk of
developing total hypercalcemia (HR, 6.66; 95% CI,
3.41–13.02; P < .001). When adjusted for frequency of
sampling, the study population included 174 nona-
zotemic cats, of which 8 developed total hypercalcemia,
and 172 CKD cases, of which 30 cats developed hyper-
calcemia. The incidence rate of total hypercalcemia was
0.02 per patient-year for the nonazotemic group and
Table 3. Clinicopathological variables for cats included in the retrospective cohort study grouped according to renal
status and development of total hypercalcemia.
Variable
(Reference Interval)
H-NCa (n = 166) H-HCa (n = 10) CKD-NCa (n = 131) CKD-HCa (n = 60)
Median [25th,
75th Percentile] n
Median [25th,
75th Percentile] n
Median [25th,
75th Percentile] n
Median [25th,
75th Percentile] n
Age (years) 12.0 [10.4, 14.0]a 161 13.9 [10.6, 14.7] 10 14.6 [12.0, 16.1]b 117 13.8 [12.0, 15.7]b 56
Weight (kg) 4.43 [3.53, 5.29]a 161 4.29 [3.71, 5.76] 10 3.94 [3.39, 4.71]b 128 4.16 [3.21, 4.94] 60
% Male 49 166 30 10 52 131 43 60
% Longhair 18 166 20 10 15 131 12 60
Albumin (2.5–4.5 g/dL) 3.2 [3.1, 3.4] 166 3.4 [3.2, 3.5] 10 3.1 [3.0, 3.3] 131 3.1 [2.9, 3.4] 60
Calcidiol (65–170 nmol/L) – 0 – 0 140.5 [128.3, 171.5] 14 144.0 [110.0, 211.0] 11
Calcitriol (90–342 pmol/L) – 0 – 0 418.0 [366.0, 447.0] 15 320.0 [116.0, 475.0] 11
Chloride (100–124 mEq/L) 119 [117, 120] 166 118 [117, 120] 10 118 [116, 121] 131 118 [116, 120] 60
Creatinine
(0.23–2.00 mg/dL)
1.47 [1.34, 1.70]a 166 1.59 [1.34, 2.04]a 10 2.37 [2.13, 2.68]b 131 2.42 [2.19, 2.90]b 60
FGF-23 (56–700 pg/mL) 164 [108, 243]a 57 261 [221, 604] 6 491 [283, 1035]b 62 518 [342, 1701]b 29
iCa (4.76–5.48 mg/dL) 5.08 [5.00, 5.24] 35 5.16 [–] 3 5.16 [5.02, 5.32]a 37 5.34 [5.20, 5.44]b 24
PCV (30–45%) 38 [34, 40]a 162 39 [36, 42] 10 35 [31, 38]b 129 35 [30, 39] 59
Venous pH (7.21–7.44) 7.35 [7.32, 7.38] 35 7.35 [–] 3 7.36 [7.31, 7.39] 33 7.35 [7.31, 7.37] 22
Phosphate
(2.79–6.81 mg/dL)
3.84 [3.35, 4.37] 166 3.53 [3.18, 4.46] 10 4.03 [3.50, 4.84] 131 4.12 [3.43, 4.95] 60
Potassium (3.5–5.5 mEq/L) 3.9 [3.7, 4.3] 164 4.0 [3.8, 4.2] 10 4.0 [3.7, 4.3] 130 4.1 [3.8, 4.3] 60
PTH (2.6–17.6 pg/mL) 7.0 [2.6, 12.0]a 31 4.6 [2.6, 7.1]a 4 15.0 [8.7, 27.7]b 62 7.9 [2.6, 22.0]a 30
SBP (<160 mmHg) 136 [122, 152] 165 134 [121, 159] 10 142 [126,158] 131 138 [123, 156] 60
Sodium (145–157 mEq/L) 152.3 [150.9, 153.8] 165 151.9 [150.5, 153.9] 10 152.5 [150.8, 154.6] 130 152.9 [150.0, 154.6] 60
tCa (8.2–11.8 mg/dL) 9.8 [9.5, 10.2]a 166 10.6 [9.7, 11.3]b 10 10.1 [9.7, 10.4]b,c 131 10.4 [10.0, 11.0]b,d 60
Total protein (6.0–8.0 g/dL) 7.6 [7.3, 8.1] 166 7.5 [7.1, 7.8] 10 7.8 [7.4, 8.1] 131 7.7 [7.4, 8.1] 60
Urea (7.0–27.7 mg/dL) 29.1 [24.9, 32.8]a 166 27.8 [24.3, 33.8]a 10 47.3 [39.9, 55.7]b 131 45.4 [37.7, 55.6]b 60
USG (≥1.035) 1.044 [1.031, 1.056]a 108 1.060 [1.041, 1.070]a 5 1.020 [1.016, 1.022]b 101 1.020 [1.016, 1.024]b 44
Follow-up (days) 732 [516, 1023]a 166 386 [166, 542]b 10 679 [490, 1022]a 131 175 [63, 403]b 60
H-NCa, apparently healthy-normocalcemic; H-HCa, apparently healthy-developed hypercalcemia; CKD-NCa, CKD-normocalcemic;
CKD-HCa, CKD-developed hypercalcemia; n, number of cats; FGF-23, fibroblast growth factor 23; PTH, parathyroid hormone; SBP, sys-
tolic blood pressure; USG, urine specific gravity; P, significance.
Rows bearing a different superscript letter are significantly different from one another.
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0.08 per patient-year for the CKD group. The Kaplan–
Meier curves (Fig 2B) remained significantly different
(P < .001) as did the hazards for incident total hyper-
calcemia (HR, 4.29; 95% CI, 1.96–9.37; P < .001).
In cats with azotemic CKD, univariable Cox regres-
sion identified higher baseline plasma tCa and creatinine
concentrations, and lower baseline plasma chloride and
PTH concentrations associated with incident total
hypercalcemia at the 10% level (Table 4). Only higher
baseline tCa was an independent predictor in the final
multivariable model (HR, 2.55; 95% CI, 1.68–3.87;
P < .001). Both higher plasma tCa and higher crea-
tinine concentrations were independent predictors of
incident total hypercalcemia in the multivariable time-
dependent Cox regression model (Table 5).
In the nonazotemic group, higher baseline plasma
tCa and creatinine concentrations were associated with
incident total hypercalcemia (Table 4). In multivariable
analysis, only tCa (HR, 5.92; 95% CI, 2.21–15.83;
P < .001) was a significant independent predictor. A
time-dependent Cox regression model was not con-
structed because no variable was significant with a type
I error <10% in univariable analysis (data not shown).
Based on ROC curve analysis, the diagnostic accu-
racy for baseline tCa to predict incident total hypercal-
cemia was fair at best with AUROC of 0.69 (95% CI,
0.62–0.77) for the CKD group and 0.75 (95% CI, 0.58–
0.93) for the nonazotemic group (Fig 3). In the CKD
group, a baseline tCa cutoff of 9.7 mg/dL had a sensi-
tivity of 96.7% (95% CI, 88.5–99.6; specificity 26.7%),
whereas a cutoff of 11.2 mg/dL had a specificity of
94.7% (95% CI, 89.3–97.8; sensitivity 16.7%). In nona-
zotemic cases, a baseline tCa cutoff of 10.1 mg/dL had
a sensitivity of 70.0% (95% CI, 34.8–93.3) and a speci-
ficity of 71.7% (95% CI, 64.2–78.4) to predict incident
total hypercalcemia.
Discussion
Results of our retrospective study show that cats with
azotemic CKD were more likely to develop total hyper-
calcemia than nonazotemic cats. Higher baseline tCa
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Fig 2. Kaplan–Meier curves illustrating the development of total
hypercalcemia in nonazotemic cats and cats with azotemic chronic
kidney disease (CKD). (A) Nonadjusted model. CKD cats (blue
curve) were at increased risk of developing total hypercalcemia
(n = 191: 60 developed total hypercalcemia, 131 censored) com-
pared to nonazotemic cats (NA, black curve, n = 176: 10 developed
total hypercalcemia, 166 censored) with a hazard ratio (HR) of 6.66
(95% confidence interval [CI], 3.41–13.02; P < .001). (B) Model
adjusted for frequency of blood sampling. CKD cases (blue curve,
n = 172: 30 developed total hypercalcemia, 142 censored) remain at
increased risk of total hypercalcemia compared to nonazotemic cats
(NA, black curve, n = 174: 8 developed total hypercalcemia, 166
censored) with a HR of 4.29 (95% CI, 1.96–9.37; P < .001).
Table 4. Univariable time-invariant Cox regression
results identifying baseline predictors of total hypercal-
cemia in cats stratified by renal status.
n HR (95% CI) P
CKD cats
Total calcium (mg/dL) 191 2.55 (1.68–3.87) <.001
PTH (<9.0 pg/mL) 32 .025
9.0–25.0 pg/mL 32 0.38 (0.16–0.89) .026
>25.0 pg/mL 28 0.36 (0.14–0.92) .033
Creatinine (mg/dL) 191 1.42 (0.96–2.10) .076
Chloride (mEq/L) 191 0.93 (0.86–1.01) .089
Nonazotemic cats
Total calcium (mg/dL) 176 5.92 (2.21–15.83) <.001
Creatinine (mg/dL) 176 5.95 (0.99–35.61) .051
CKD, chronic kidney disease; n, number of cats; HR, hazard
ratio; 95% CI, 95% confidence interval; PTH, parathyroid hor-
mone; P, significance.
Table 5. Univariable and multivariable time-dependent
Cox regression results identifying risk factors for inci-
dent total hypercalcemia in cats with azotemic CKD
(n = 191).
HR (95% CI) P
Univariable results
Total calcium (mg/dL) 2.40 (2.05–2.80) <.001
Creatinine (mg/dL) 1.28 (1.05–1.55) .015
Multivariable results
Total calcium (mg/dL) 2.42 (2.07–2.84) <.001
Creatinine (mg/dL) 1.28 (1.05–1.56) .017
n, number of cats; CKD, chronic kidney disease; HR, hazard
ratio; 95% CI, 95% confidence interval; P, significance.
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predicted incident total hypercalcemia in both azotemic
and nonazotemic animals. At any time, higher plasma
tCa and creatinine concentrations were associated with
incident total hypercalcemia in cats with azotemic
CKD. The majority of cats with total hypercalcemia
had concomitant ionized hypercalcemia. Conversely,
underestimation of iCa by tCa was common and associ-
ated with lower venous HCO3
, and plasma albumin
and creatinine concentrations.
Although the biologically active ionized calcium frac-
tion most accurately reflects true calcium status, tCa
usually is relied on in practice. Total calcium concentra-
tion only shows moderate association with iCa in cats.
The correlation of plasma tCa to whole blood iCa
found in this study (r = 0.63) is similar to the previously
reported correlation for cats with CKD (r = 0.68).10
This association was found to be higher in the general
population (r = 0.87),10 but here the association in non-
azotemic cats (r = 0.62) was similar to that in cats with
renal azotemia. Differences in age and sample handling
could have accounted for this observation. Age was not
a selection criterion in the previous study,10 whereas
nonazotemic cats in our study were ≥9 years. Both ana-
lytes were measured in serum in the previous study,
whereas in our study iCa was measured in whole blood
directly after sampling, and tCa was measured in hep-
arinized plasma.
In contrast to the concept that hypercalcemia in cats
with CKD generally represents an increase in tCa
only,12–14 the majority of cats with hypercalcemia based
on tCa in our study had a coexistent increase in iCa.
Specificity for tCa to detect ionized hypercalcemia was
close to 100%, which is in agreement with high speci-
ficity values reported previously for cats10 and humans15
with CKD, but dissimilar to the situation in dogs with
CKD, in which tCa tends to overestimate iCa.25
A large proportion of ionized hypercalcemic cats had
a normal tCa in the cross-sectional study. The ROC
curve analysis showed that the possibility of ionized
hypercalcemia should be considered if tCa is within the
upper half of the reference interval. Low sensitivity of
tCa to detect ionized hypercalcemia has been reported
previously in humans15 and cats10 with CKD, and was
associated with lower total CO2 and albumin concentra-
tions in human CKD patients.15 Our study identified
lower HCO3
 as a risk factor for failure of tCa to
detect ionized hypercalcemia in cats. Noncorrected tCa
previously was shown to be influenced by HCO3
 and
albumin concentrations in human CKD patients with
underestimated iCa.15 In agreement with this finding,
HCO3
, albumin, and creatinine were identified as pre-
dictors of tCa in cats with CKD. These associations
were independent of iCa, and lower concentrations of
these analytes could therefore increase the risk for
underestimation of iCa.
Bicarbonate concentration, reflecting acid-base status,
affects plasma calcium concentration by influencing bone
storage,26–28 protein binding,29 and tubular reabsorption
of calcium.30 Metabolic acidosis stimulates osteoclastic
bone resorption,26–28 but decreases the protein-bound
calcium fraction as calcium and hydrogen ions compete
for albumin binding sites.29,31 Free and complexed cal-
cium concentrations could possibly increase as a result,
but these ultrafilterable fractions are under control of
renal regulation.32 Indeed, metabolic acidosis was associ-
ated with increased urinary calcium excretion in
dogs,30,33 whereas iCa did not appear affected.34 How-
ever, if renal calcium excretion were to be impaired, ion-
ized hypercalcemia could occur in conjunction with total
normocalcemia. The association between creatinine and
tCa supports a role for metabolic acidosis, because its
prevalence increases with a decrease in kidney function.35
Conversely, a higher HCO3
 is expected to increase tCa
by stimulation of tubular calcium reabsorption30 and
increased protein binding,29 as reflected by the iCa-inde-
pendent association between HCO3
 and tCa found in
the cross-sectional analysis.
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Fig 3. Receiver operating characteristic (ROC) curves illustrating
the predictive ability of different baseline plasma tCa for develop-
ment of total hypercalcemia in (A) chronic kidney disease (CKD)
and (B) nonazotemic cats. Diagnostic accuracy of the model was
poor in CKD cases (area under the ROC curve [AUROC], 0.69;
95% confidence interval [CI], 0.62–0.77; P < .0001) and fair in
nonazotemic cases (AUROC, 0.75; 95% CI, 0.58–0.93; P = .0078).
Points on the graphs illustrate decision thresholds of baseline tCa
for the prediction of incident total hypercalcemia during follow-up
(tCa reference interval: 8.20–11.80 mg/dL). AUC, area under the
curve; P, significance.
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A lower albumin concentration would decrease the
protein-bound calcium fraction36 and was found to
increase risk of underestimation. Historically, correction
formulas were developed in an attempt to adjust tCa
for albumin binding in humans37 and dogs,38 but not
for cats because of the particularly weak association
between calcium and albumin in this species.16,17 Cor-
rection formulas currently are considered obsolete due
to poor performance.15,25
The finding that creatinine was independently associ-
ated with tCa in CKD cats could be indicative not only
of a role for metabolic acidosis, but also for increased
availability of calcium-binding anions. In dogs with
CKD, tCa is mainly influenced by increases in the com-
plexed calcium fraction, which underlies the tendency of
tCa to overestimate the prevalence of ionized hypercal-
cemia in that species.39 Data on the plasma concentra-
tions of most calcium-binding anions were not available
for our study, except for phosphate, which showed no
association with risk of underestimation (P = .802).
Results from our retrospective cohort study show
that cats with CKD are at risk for the development of
total hypercalcemia. Sixty of 191 cats (31.4%) devel-
oped total hypercalcemia at a median of 175 [63, 403]
days after diagnosis of azotemic CKD. Total hypercal-
cemia previously was reported with a prevalence of 10–
32% of cats with CKD,1,3,5,10 and incident hypercal-
cemia, with both tCa and iCa increased, in 2 of 15 cats
within 6 months after diagnosis of CKD.40
The 3 most common causes of hypercalcemia in
human CKD patients are neoplasia, hyperparathy-
roidism, and milk-alkali syndrome.41 In a previous publi-
cation on total hypercalcemia in cats, 6 of 33 azotemic
cats had concurrent neoplastic disease, and 9 had concur-
rent urolithiasis,2 and in our study, abdominal masses
and calcium oxalate crystalluria were identified in 2 cases
each. Ionized hypercalcemia in cats with CKD is thought
to occur secondary to severe renal hyperparathyroidism,
or as a result of administration of vitamin D metabolites
(eg, calcitriol).42 Hypervitaminosis D appears to be an
unlikely cause of total hypercalcemia in our study,43
because none of the cats were known to have been
exposed to or had been treated with vitamin D analogues
or metabolites. Furthermore, plasma phosphate concen-
trations were generally within the reference interval. Sev-
ere hyperparathyroidism cannot be ruled out. Plasma
PTH concentrations were not available in most cats at
the hypercalcemic visit. In cats with total hypercalcemia
that had PTH measured, concentrations were low and
generally had decreased compared to baseline. In a
previous study, plasma PTH concentrations of cats
that developed hypercalcemia after diagnosis of CKD
decreased to below the lowest limit of detection of
the assay,40 which also is a common finding in cats
with idiopathic hypercalcemia.g,4 Idiopathic hypercal-
cemia could have been the underlying cause of total
hypercalcemia in our study in the nonazotemic group
as well as possibly in the cats with concurrent
CKD.g,4 However, in our study, other causes of
hypercalcemia were not completely excluded because
investigations such as diagnostic imaging were not
performed, and therefore, a confirmed diagnosis of
idiopathic hypercalcemia in the nonazotemic cats can-
not be made. It also remains unclear what role
pathophysiological mechanisms resulting in idiopathic
hypercalcemia might play in the development of total
hypercalcemia in azotemic cats.
Phosphate restriction potentially could contribute to
development of hypercalcemia in CKD, because with-
drawal of dietary phosphate restriction restored normo-
calcemia in 1 study.40 A randomized placebo-controlled
clinical trial in human CKD patients not on dialysis
showed that phosphate-binding treatment led to pro-
gressive vascular calcification,44 even with calcium-free
binders. The authors hypothesized that intestinal cal-
cium would be more readily absorbed with phosphate
restriction. Higher PO intake of calcium has been
shown to result in hypercalcemia in children with
CKD.45 Other dietary factors, such as potassium and
any accompanying bicarbonate-generating organic
anion, also are involved in calcium homeostasis.46
Baseline tCa was significantly higher in cats that
developed total hypercalcemia and predicted incident
total hypercalcemia in both nonazotemic cats and cats
with azotemic CKD. In cats with renal azotemia, a
higher tCa at any time point was associated with inci-
dent total hypercalcemia independent of severity of azo-
temia. Higher plasma calcium concentrations, and
ultimately hypercalcemia, could have been caused by
several mechanisms. Polymorphisms in the calcium-sen-
sing receptor have been identified in cats.h,47 and were
associated with higher serum tCa in healthy women48,49
and in human end-stage CKD patients.50 Decreased
bone formation is a known consequence of CKD in
humans, leading to inability of bone to buffer changes
in serum calcium concentration.51,52 Five cats received
aluminum-containing phosphate binders, the use of
which has been associated with low bone turnover and
hypercalcemia in human CKD patients.53
Higher plasma creatinine concentrations at any time
point were associated with incident total hypercalcemia
independent of tCa in cats with CKD. The prevalence
of total hypercalcemia was shown to increase with
severity of CKD previously, from 8% in early stage
kidney disease to 32% in end-stage CKD.1 As discussed
above, a decline in kidney function could contribute to
an increase in calcium-containing ionic complexes, as
has been shown in dogs with CKD.39 Metabolic acido-
sis is found with increasing frequency in cats as renal
function declines.35 In rodent models, metabolic acido-
sis has been documented to stimulate osteoclastic bone
resorption,54 releasing calcium carbonate into the
circulation.27 Increased bone resorption and decreased
bone mineral density are known consequences of CKD
in cats.55 Interestingly, previous studies of cats report
that hypochloremia develops before manifestation of
metabolic acidosis in cats with CKD,56 possibly in an
attempt to maintain HCO3
 concentrations within nor-
mal limits.57 In our study, lower baseline plasma chlo-
ride concentrations appeared associated with incident
total hypercalcemia with a type I error <10% in uni-
variable analysis (P = .089). Therefore, an increased
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requirement for skeletal buffering of acid could be
related to total hypercalcemia in cats with CKD. Fur-
ther work is warranted to test this hypothesis.
By contrast, milk-alkali syndrome is a form of hyper-
calcemia in CKD associated with metabolic alkalosis,
often caused by ingestion of calcium carbonate.41 Alkali
ingestion, tubular reabsorption of HCO3
, and suppres-
sion of PTH contribute to metabolic alkalosis,41 which in
turn leads to increased tubular calcium reabsorption.30,33
Cats in the retrospective cohort were not treated with cal-
cium carbonate, and classic milk-alkali syndrome is unli-
kely to have caused total hypercalcemia. However,
HCO3
 was positively associated with tCa in the cross-
sectional analysis, and it could be hypothesized that
higher tCa could in part be due to bicarbonate-induced
increases in tubular calcium reabsorption.
Our study had a number of limitations because of its
retrospective design. Cats ate a wide variety of commer-
cial cat foods at baseline, and all CKD cats were
offered a phosphate-restricted renal diet for manage-
ment of their disease, but precise data on what propor-
tion of the renal diet was fed and other dietary
contributions often were unavailable. Data on dietary
calcium and vitamin D concentrations were not avail-
able. Therefore, no conclusions could be drawn on any
possible dietary interaction.
Although no diagnosis other than azotemic CKD was
made in the majority of primary care cases presented,
concurrent conditions, including occult neoplasia and
hyperparathyroidism, cannot be ruled out because diag-
nostic tests other than biochemistry and urinalysis were
not consistently performed. Lack of blood gas data pro-
hibited evaluation of the effect of acid-base disturbances
on development of total hypercalcemia.
Classification of cohort cases was based purely on
tCa. Because of low sensitivity of tCa to detect ionized
hypercalcemia, ionized hypercalcemic cats likely were
misclassified in the normocalcemic groups. Although
our study focused on total hypercalcemia, factors affect-
ing iCa could be expected to influence tCa, and differ-
ences between cats that remained normocalcemic and
cats that developed total hypercalcemia could have been
missed due to misclassification.
Our study highlights the importance of hypercalcemia
in cats with CKD because total hypercalcemia devel-
oped in 60 of 191 cats (31.4%). The supposition that
hypercalcemia in cats with CKD represents total hyper-
calcemia only, with the biologically active ionized cal-
cium fraction adequately regulated and within its
reference interval, should be questioned. Supported by
the high specificity reported here and previously,10 most
cats with total hypercalcemia are suspected to have ion-
ized hypercalcemia. Sensitivity of tCa to detect ionized
hypercalcemia is low, and therefore measurement of iCa
is a necessity for accurate assessment of calcium status
in cats. In human medicine, increased serum calcium
concentrations as part of chronic kidney disease-mineral
and bone disorder (CKD-MBD) have been associated
with vascular calcification,58–60 cardiovascular morbid-
ity, and increased mortality.61,62 Similarly, in cats, pre-
vious case reports have identified calcification of the
aorta, gastric wall, paws, and kidneys associated with a
high calcium-phosphorus product, although the full
extent of soft tissue mineralization as a component of
CKD-MBD in cats remains to be fully elucidated.3,63–67
Higher baseline tCa did not predict all-cause mortality
in cats with CKD,68 but underdiagnosis of ionized
hypercalcemia may have impacted these results and
therefore the full effect of hypercalcemia on prognosis
in cats with CKD remains to be determined. Prospec-
tive studies that longitudinally assess iCa throughout
the course of CKD are warranted to further understand
both the biochemical and clinical consequences of cal-
cium derangements in cats with CKD.
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b i-STAT 1 point-of-care analyzer, Abbott Point of Care Inc.,
Princeton, NJ
c FGF-23 ELISA Kit, Kainos Laboratories, Tokyo, Japan
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g Schenck PA, Chew DJ, Refsal K, Nachreiner R, Rick M. Cal-
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